United States: The Value Of Being Highly Similar: First U.S. Biosimilar

Last Updated: April 23 2015
Article by Irena Royzman

The Biologics Price Competition and Innovation Act of 2009 (BPCIA) was passed as part of health reform, the Affordable Care Act, signed into law by President Barack Obama in March 2010. The BPCIA created an abbreviated regulatory pathway for marketing approval of biologic medicinal products that are ''biosimilar'' to an already approved product. On March 6, the Food and Drug Administration (FDA) approved the first biosimilar in U.S. history—Sandoz's biosimilar of Amgen's blockbuster drug used to prevent infections in cancer patients, Neupogen. Sandoz, a Novartis company, reaped tremendous savings in cost and time by taking advantage of the new biosimilar pathway rather than submitting a full biologics license application (BLA) to the FDA and undertaking all the studies that Amgen had to perform to obtain approval for Neupogen. The extent to which these savings will be passed on to the U.S. health care system as envisioned by the Obama administration, however, is less clear.

Biologic medicines, also known as biologics, are complex molecules that are made in living cells rather than chemically synthesized, as are the more familiar pharmaceutical products known as chemical or smallmolecule drugs. Because biologics are made in living cells, they, at most, can be similar to already approved biologics and are governed by a separate regulatory scheme than small-molecule drugs. The BPCIA permits a biosimilar maker to rely on the safety and effectiveness of the already approved biologic product, enabling a biosimilar product to gain FDA approval based on less than a full complement of preclinical and clinical data.

Landmark Year for Biosimilars in U.S.

After a slow start for the biosimilar pathway, 2015 has been a landmark year. The FDA approved Sandoz's Neupogen biosimilar, to be sold under the trade name Zarxio. Sandoz's product has been sold in the European market under the trade name Zarzio since 2009, when the European Medicines Agency (EMA) approved it as a biosimilar to Amgen's Neupogen and allowed it to be marketed for all the same medical uses as Neupogen. Since 2013, just four years after Sandoz's Zarzio became available to patients across Europe, Zarzio overtook Amgen's Neupogen as the market leader.

As in Europe, the FDA approved Zarxio for all of Neupogen's medical uses, even though Sandoz had conducted clinical trials for only one of them. The approval and its scope are not surprising. Neupogen is one of the simplest biologics on the market, making it easier to achieve biosimilarity. Sandoz's product has been sold in more than 40 countries worldwide, leading to more than 7 million patient exposure days to the product. After reviewing Sandoz's submission, the FDA concluded earlier this year that Zarxio is a biosimilar of Neupogen, i.e., that it is ''highly similar'' to Amgen's Neupogen with ''no clinically meaningful differences'' between Zarxio and Neupogen ''in terms of the safety, purity, and potency of the product.''

The FDA determined that it was scientifically justified to extrapolate the clinical data submitted by Sandoz for one indication to all five of Neupogen's indications. The potential for extrapolation is a key advantage of the biosimilar pathway as it shortcuts the need for clinical trials for each indication and therefore significantly reduces the time and expense of approval. It took Amgen an additional seven years and extensive clinical trials to obtain all five of Neupogen's indications after the FDA first approved Neupogen for one of them in 1991.

Different Story for Teva's Granix

Zarxio will not be the first version of Amgen's Neupogen in the U.S. Teva has sold a version of Amgen's Neupogen, under the trade name Granix, since 2013 after obtaining FDA approval through the submission of a full biologics license application. Teva has obtained about 14 percent of the Neupogen market after reducing the price of Granix by approximately 20 percent compared to Neupogen. The annual cost for a Granix 10-dose package was approximately 20 percent lower compared with the 10-dose package of Neupogen prefilled syringes or vials ($3,525 versus $4,939 and $4,659, respectively).

Teva submitted its regulatory application for Granix in December 2009, shortly before the BPCIA was enacted. Because Teva, unlike Sandoz, did not go through the biosimilar pathway, it could not rely on Amgen's clinical studies and obtained approval for only one of five of Neupogen's indications—the only one for which Teva provided clinical studies to the FDA. In Europe, by contrast, Teva sells the same product as a biosimilar of Amgen's Neupogen. The EMA granted Teva's biosimilar product all the same medical uses as for Neupogen in 2008. Teva may have been able sell Granix as a biosimilar in the U.S. if it waited for the BPCIA to become law before submitting its regulatory application to FDA.

In addition to not obtaining all the indications for Neupogen, Teva, unlike Sandoz, is not able to market its product as highly similar, i.e., a biosimilar, to Neupogen. Medicare reimbursement also is more favorable to Sandoz's biosimilar product than Teva's Granix.

Reimbursement, Pricing Variations

To encourage physicians to prescribe biosimilar products, the Affordable Care Act sets the reimbursement of biosimilar drugs as their average selling price plus 6 percent of the innovator drug's average selling price. This reimbursement scheme provides physicians with the same margin, 6 percent of the innovator drug's average selling price, regardless of whether the physician administers the innovator or the biosimilar product. The value of reimbursement for Zarxio therefore will be its average selling price plus 6 percent of Amgen's price for Neupogen. Because Teva's Granix was not approved through the biosimilar pathway, its reimbursement is calculated as its average selling price plus 6 percent of its own price, which is approximately 20 percent less than that for Amgen's Neupogen. Physicians therefore would obtain a greater margin from prescribing Sandoz's Zarxio than Teva's Granix. In addition, because a Zarxio-specific average selling price would not be available for up to two quarters after launch, payers can choose to set the level of reimbursement for Zarxio at the same level as Amgen's Neupogen during that time.

Given the many advantages of proceeding through the biosimilar pathway, it is perhaps surprising that when Sandoz's Global Head of Development for Biopharmaceuticals and Oncology Injectables, Mark Mc- Manish, was asked at the FDA's Advisory Committee meeting how Sandoz planned to price its product, he could not confirm that Sandoz would price below Amgen's price for Neupogen ''because in some situation[s], the price will be at parity.'' Thus, while it is clear that the biosimilar pathway offers tremendous benefits to biosimilar manufacturers, the reports on the first U.S. biosimilar raise the question as to the extent to which those savings will be passed down to the U.S. health care system.

In Europe, by contrast, Sandoz's Neupogen biosimilar has been reported to provide approximately a 25 percent to 30 percent cost-saving over Neupogen and Sandoz's product is the market leader. The same ultimately may be the case in the U.S. even if Sandoz initially prices Zarxio at parity with Amgen's Neupogen. But the competitive landscape is different in Europe than in the U.S. In Europe, Teva's biosimilar to Neupogen was approved first and was approved for all of Neupogen's medical uses. In the U.S., Teva's Granix is first but Sandoz's Zarxio is the first biosimilar and the only product approved for all of Neupogen's medical uses. In addition, the U.S. and Europe differ in reimbursement practices and incentives. As a result, the extent to which the cost-savings seen in Europe provide a precedent that is applicable to the U.S. is far from clear.

Litigation May Control Zarxio Release Timing

It also is not clear when Zarxio will reach the market and whether it will reap the advantage of being the first biosimilar of Neupogen to be approved in the U.S. The timing will depend on Amgen's lawsuit against Sandoz for violating the BPCIA, while taking advantage of Amgen's extensive preclinical and clinical data to obtain regulatory approval. Amgen is seeking to prevent Zarxio from entering the market until Sandoz complies with the BPCIA's litigation procedures and until all patent disputes are resolved. A federal court in California heard Amgen's arguments on March 13 but denied Amgen's request for an injunction against Sandoz. Amgen appealed the district court decision to the Federal Circuit on March 25 and is seeking an injunction while the appeal is pending.

Given the importance of the case, Amgen and Sandoz agreed to expedite appellate briefing and to request an early date for oral argument, potentially as soon as the Federal Circuit's June calendar. Sandoz is not launching Zarxio in the meanwhile. It has agreed not to enter the market until May 11, 2015, or a decision by the Federal Circuit on Amgen's request for an injunction pending appeal, whichever comes sooner. The timing of market entry determines whether Zarxio will be the first biosimilar on sale in the U.S. or lose the competitive advantage of being first since the FDA is already reviewing a second potential biosimilar of Neupogen, Apotex's version, and Apotex's product may be approved later this year. The FDA also is reviewing Apotex's potential biosimilar of Amgen's Neulasta, a longacting version of Neupogen, and it may be approved later this year as well.

Previously published in Life Sciences Law & Industry Report, 9 LSLR 459, 04/17/2015.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Patterson Belknap Webb & Tyler LLP
Patterson Belknap Webb & Tyler LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Patterson Belknap Webb & Tyler LLP
Patterson Belknap Webb & Tyler LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions